Literature DB >> 2187002

The treatment of heroin addicts with dextromethorphan: a double-blind comparison of dextromethorphan with chlorpromazine.

H Koyuncuoğlu1, B Saydam.   

Abstract

According to the hypothesis that the development of physical dependence on and tolerance to opiates depends on the inhibition by opiates of L-asparaginase and L-glutaminase activities in the brain, and the blockade by opiates of the aspartatergic/glutamatergic receptors especially NMDA, four female and fourty-four male heroin addicts were included in a double-blind clinical trial. Four mg chlorpromazine (CPZ) was administered every hour and 10 mg diazepam (DIA) every 6 hours to a group consisting of two female and nineteen male inpatients. The remaining subjects received 15 mg non-opioid antitussive dextromethorphan (DM) instead of CPZ. The withdrawn addicts were controlled twice a day and yawning, lacrimation, rhinorrhoea, perspiration, goose flesh, muscle tremor, dilated pupils, anorexia, joint and muscle aches, restlessness, insomnia, emesis, diarrhea, craving and rejection of smoking as abstinence syndrome signs were observed and rated on a scale of 1, 2 and 3 points according to their intensity. All signs, except perspiration and emesis, were significantly less intense in the group given DM + DIA than CPZ + DIA. The other plus points included the immediate stop of craving and the early onset of smoking in DM + DIA group. The results are considered to be supporting evidence for the hypothesis emphasizing the blockade of NMDA receptors by opiates in opiate addiction. Furthermore, the decrease caused by non-opioid NMDA antagonists in the responsiveness of NMDA receptors appears very promising for the treatment of opiate addicts.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2187002

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  8 in total

Review 1.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

Review 2.  Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations.

Authors:  Caroline A Arout; Ellen Edens; Ismene L Petrakis; Mehmet Sofuoglu
Journal:  CNS Drugs       Date:  2015-06       Impact factor: 5.749

3.  Evaluation of the reinforcing and subjective effects of heroin in combination with dextromethorphan and quinidine.

Authors:  Suzanne K Vosburg; Maria A Sullivan; Sandra D Comer
Journal:  J Opioid Manag       Date:  2011 Nov-Dec

4.  Dextromethorphan and quinidine combination for heroin detoxification.

Authors:  Evaristo Akerele; Adam Bisaga; Maria A Sullivan; Fatima Garawi; Sandra D Comer; Anil A Thomas; Edward V Nunes; Herbert D Kleber
Journal:  Am J Addict       Date:  2008 May-Jun

5.  The neurobiology of opiate tolerance, dependence and sensitization: mechanisms of NMDA receptor-dependent synaptic plasticity.

Authors:  Keith A Trujillo
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

6.  Comparison of the efficacy of adding clonidine, chlorpromazine, promethazine, and midazolam to morphine pumps in postoperative pain control of addicted patients.

Authors:  Farnad Imani; Poupak Rahimzadeh; Seyyed Hamid Reza Faiz
Journal:  Anesth Pain Med       Date:  2011-07-01

7.  Heterogeneous network propagation with forward similarity integration to enhance drug-target association prediction.

Authors:  Piyanut Tangmanussukum; Thitipong Kawichai; Apichat Suratanee; Kitiporn Plaimas
Journal:  PeerJ Comput Sci       Date:  2022-10-11

8.  The therapeutic effect of adding dextromethorphan to clonidine for reducing symptoms of opioid withdrawal: a randomized clinical trial.

Authors:  Ayyoub Malek; Shahrokh Amiri; Bohlool Habibi Asl
Journal:  ISRN Psychiatry       Date:  2013-06-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.